Leptin may support the proliferation and hinder the apoptosis of tumor cells. Although leptin expression has been studied in several human tumors, its potential clinical significance remains uncertain in patients with gastric carcinoma. Furthermore, the majority of available findings have been determined from preclinical studies using stomach carcinoma tissue section and, to date, few studies have evaluated the clinical significance of leptin in the serum or plasma of gastric carcinoma patients. In the current study, the serum concentration of soluble leptin was assessed in gastric carcinoma patients, and its contributions to the clinical parameters and prognosis of patients were determined. A total of 63 pathologically confirmed gastric cancer patients and 30 healthy subjects were enrolled in the study and circulating leptin levels in the serum of all subjects were determined by ELISA. The serum leptin concentrations were significantly lower in the gastric cancer patients compared with the healthy control group (P = 0.009). In the gastric cancer patients, the clinical features of patient age, sex, lesion localization, histopathology, pathological grade, stage of disease, and serum tumor markers including lactate dehydrogenase, carcinoembryonic antigen, and carbohydrate antigen 19–9 were not correlated with serum leptin concentration. Furthermore, no association was observed between serum leptin concentration and responsiveness to chemotherapy (P = 0.51), and leptin level had no apparent prognostic role in clinical outcome (P = 0.57). In conclusion, although it was not predictive or prognostic, serum leptin level may be a valuable diagnostic indicator in patients with gastric carcinoma.

中文翻译：

---

胃癌患者血清瘦素水平的临床意义。

瘦素可能支持肿瘤细胞的增殖并阻止其凋亡。尽管已经在几种人类肿瘤中研究了瘦蛋白的表达，但是在胃癌患者中其潜在的临床意义仍然不确定。此外，大部分可利用的发现是通过使用胃癌组织切片的临床前研究确定的，迄今为止，很少有研究评估瘦素在胃癌患者血清或血浆中的临床意义。在本研究中，评估了胃癌患者血清中可溶性瘦素的浓度，并确定了其对临床参数和患者预后的贡献。共有63名经病理证实的胃癌患者和30名健康受试者入选了该研究，并通过ELISA测定了所有受试者血清中的瘦素水平。与健康对照组相比，胃癌患者的血清瘦素浓度显着降低（P = 0.009）。在胃癌患者中，患者年龄，性别，病变部位，组织病理学，病理分级，疾病分期以及血清肿瘤标志物（包括乳酸脱氢酶，癌胚抗原和糖类抗原19-9）的临床特征与血清瘦素无关浓度。此外，在血清瘦素浓度和对化疗的反应性之间未发现关联（P = 0.51），瘦素水平在临床结果中没有明显的预后作用（P = 0.57）。总之，尽管血清瘦素水平不能预测或预测预后，但对胃癌患者可能是有价值的诊断指标。